Pakistan

Pakistan has a restrictive controlled-substance regime, with classic psychedelics generally falling outside routine clinical access and remaining available, if at all, only within authorisation for medical, scientific or industrial purposes. The ecosystem appears small: Blossom's linked data show one trial, no active linked trials, one linked stakeholder and no linked events, which is consistent with limited public-facing psychedelic research activity.

Ask Blossom about this country

Key Insights

A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Pakistan.

1
The legal baseline is restrictive, so any psychedelic use would need to fit an explicit medical, scientific or industrial authorisation pathway.
2
Pakistan's visible psychedelic research footprint is very small, with Blossom's linked dataset showing only one trial and no active linked studies.
3
Ketamine is the main clinically relevant adjacent substance in Pakistan, largely because it is an established anaesthetic and has been discussed in local depression literature.
4
I found no strong public evidence of an operational national programme for psychedelic-assisted therapies or formal reimbursement for such care.
5
Any claim of patient access beyond licensed research would be speculative on the evidence reviewed, so Pakistan should be treated as a review candidate rather than a clear access market.

Research Snapshot

Blossom currently tracks 1 psychedelic clinical trial connected to Pakistan.

Active trials: 0
Total trials: 1
Stakeholders: 1
Events: 0

Top Compounds

Psilocybin(1)

Medical Access Snapshot

Pakistan maintains a restrictive controlled-substance regime under the Control of Narcotic Substances Act, 1997 (CNSA), which broadly prohibits possession, manufacture, distribution and trafficking of narcotic and psychotropic substances except where specifically authorised for medical, scientific or industrial purposes. Ketamine is routinely available and used in medical settings (anesthesia) and is also used off-label in some private-sector psychiatric settings for depression, but there is no national reimbursement or formal public program for...

View trials→View stakeholders→Open access guide→

Regulatory Status

Pakistan's Control of Narcotic Substances Act 1997 broadly prohibits possession, manufacture, sale and related handling of narcotic drugs and psychotropic substances, except for medical, scientific or industrial purposes under authorisation. ANF materials show subsidiary rules governing controlled drugs and chemicals, while WHO guidance on controlled substances supports the general principle that medical and scientific access depends on a formal control system. Based on the sources reviewed, psychedelic access in Pakistan appears highly restricted and research-dependent; however, the exact practical route for any specific compound may vary by licence and was not fully verifiable from public sources.